Equon Pharmaceuticals

Equon is primed to move its antibodies into pre-clinical trials in preparation for FDA approval.

Equon is primed to move its antibodies into pre-clinical trials in preparation for FDA approval treating both Rheumatoid Arthritis and Late Phase Asthmatic Response. Due to the nature of many other autoimmune conditions, it is highly likely that Equon's antibodies will be able to treat other conditions, expanding the market opportunities. The estimated market size for those that suffer from Late Phase Asthmatic Response is 2.3 million people and there is currently no competition in the marketplace for a preventative solution such as the one Equon is proposing. Today individuals who suffer from this type of response need to seek immediate medical attention to restore the ability to breathe. When the antibodies are taken by the patient on a monthly basis, it will prevent the late phase asthmatic response from happening within the body. The target is to have FDA approval by 2019 and achieve a 25% penetration rate by 2021 with an annual sales target of $673 M. Rheumatoid Arthritis impacts an estimate of 1.5 million people. There is substantial competition in the space including drugs such as Humira. However, most of the drugs offered to treat patients with Rheumatoid Arthritis have significant side effects including but not limited to the development of cancer and in severe cases death. Equon’s antibodies will be able to provide a much safer solution with the expectation of minimal side effects. Equon forecasts FDA approval by year end 2020 and will achieve a 25% penetration rate into the market by 2023 with an annual sales estimate of $661 M. The antibody development will be following a specific series of development of which would be incredibly challenging for competitors to replicate. Some of the keys areas are the human fusion partners, a series of proteins along with the time necessary to gain FDA approval. It is for these reasons Equon will not be submitting a patent and will be keeping this process a trade secret.